ArticleFrontiers in epidemiology2025
A calibration of nucleic acid (PCR) by antibody (IgG) tests in Germany: the course of SARS-CoV-2 infections estimated.
Article in Frontiers in epidemiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In Germany, a consortium of authority-accredited laboratories (ALM) covered approximately 90% of all severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase chain reaction (PCR) tests during the COVID-19 pandemic (March 2020 until January 2023), and they likewise conducted serological mass tests for IgG antibodies until May 2021. We analyzed the ALM-observed week-resolved time courses of test-positive fractions of PCR and IgG tests, by least-squares fitting a simple function of the former to the course of the latter. Specifically, we show that scaling and shifting the cumulative sum of previous PCR-positive fractions effectively reproduces the time course of the IgG-positive fraction. The value of 0.14 found for the fitted scaling parameter means that only 14% of those who were tested PCR-positively actually became infected with SARS-CoV-2. This parameter fit further implies that a quarter of the German population already carried IgG antibodies from natural infections in their blood at the turn of the year from 2020 to 2021. To check this fit using a second, independent analysis, we took from the literature the Germany-specific ratio of 1:10 for the ratio between one positive PCR test and the corresponding number of persons actually infected with SARS-CoV-2, and therewith estimated the time course of the latter within the German population. The courses of all three fractions, i.e., both the observed and the fit-estimated IgG-positives and the fit-estimated infected, matched each other well in the period from early December 2020 to May 2021. The extrapolated courses of both the fit-estimated fractions, i.e., those of the IgG-positives and the infected, align well to perfectly with the IgG-positive fraction (92%) reported by the Robert Koch Institute at the end of 2021.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.